Search Result

Results for "

cytochrome P450 3A4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (37) 5-HT Receptor (5) Aldose Reductase (1) Antibiotic (2) Antifolate (1) Apoptosis (6) Autophagy (8) Bacterial (2) Calcium Channel (1) Dihydrofolate reductase (DHFR) (1) Dopamine Receptor (3) Drug Metabolite (8) FGFR (1) Fluorescent Dye (1) Fungal (3) Glucocorticoid Receptor (3) HIV (2) HMG-CoA Reductase (HMGCR) (1) Insecticide (1) Interleukin Related (2) Isotope-Labeled Compounds (5) MEK (1) Microtubule/Tubulin (1) Mineralocorticoid Receptor (1) Mitosis (1) MOFs (1) NAMPT (1) Opioid Receptor (1) P-glycoprotein (1) Parasite (4) Potassium Channel (3) PPAR (6) Pyruvate Kinase (1) Reference Standards (5) RET (1) Reverse Transcriptase (2) SARS-CoV (3) Serotonin Transporter (2) Sodium Channel (1) Thymidylate Synthase (1) Topoisomerase (1) Urotensin Receptor (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (10) Endocrinology (1) Infection (13) Inflammation/Immunology (10) Metabolic Disease (10) Neurological Disease (11)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

GMP Molecules

Targets Recommended: Cytochrome P450

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-17356

Fenofibrate Maximum Cited Publications 33 Publications Verification	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

HY-N6972

Cepharanthine Maximum Cited Publications 13 Publications Verification	Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite	Infection Inflammation/Immunology Cancer
Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC₉₀) values of 1.90 and 4.46 μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

HY-N0926

Columbamine 1 Publications Verification Columbamin; Dehydroisocorypalmine	Cytochrome P450 Apoptosis Parasite	Infection Neurological Disease Inflammation/Immunology Cancer
Columbamine (Columbamin; Dehydroisocorypalmine) is an organic heterotetracyclic alkaloid extracted from plants. Columbamine is a metabolite of Berberine (HY-N0716). Columbamine inhibits the cytochrome P450 (CYP) isoform CYP3A4 (IC50 = 30.6 µM). Columbamine induces apoptosis in cancer cells. Columbamine can be used for antioxidant, anti-inflammatory, antitumor, antifungal, antiparasite, hepatoprotective, neuroprotective, hypolipidemic and hypoglycemic study .

HY-157421

Nampt activator-4	NAMPT	Metabolic Disease
Nampt activator-4 is an orally active NAMPT activator, with an EC₅₀ of 58 nM and a K_a of 85.38 nM against human NAMPT. Nampt activator-4 effectively relieves the feedback inhibition of nicotinamide and NAD ⁺, thereby enhancing enzymatic activity and significantly increasing intracellular NAD ⁺ levels. Nampt activator-4 exhibits moderate stability in human and mouse liver microsomes. Nampt activator-4 shows low to moderate inhibitory effects on cytochrome P450 (especially CYP3A4). Nampt activator-4 can be used for the research of type 2 diabetes and related metabolic disorders .

HY-17570

Desoximetasone 1 Publications Verification	Glucocorticoid Receptor Interleukin Related Cytochrome P450	Inflammation/Immunology
Desoximetasone is a corticosteroid and a substrate of **cytochrome P450 3A4**. Desoximetasone has anti-inflammatory, anti-allergic, and immunosuppressive effects. Desoximetasone can be used in the research of various skin diseases, such as skin allergies, atopic dermatitis, and psoriasis .

HY-B0383

Almotriptan malate PNU180638	5-HT Receptor	Neurological Disease
Almotriptan malate (PNU180638) is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan malate shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan malate induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan malate can be used in research related to migraine .

HY-147411

Ulonivirine MK-8507	Reverse Transcriptase HIV	Infection
Ulonivirine is an orally active non-nucleoside HIV-1 reverse transcriptase inhibitor that binds to the classical non-nucleoside reverse transcriptase inhibitor hydrophobic binding pocket adjacent to the polymerase active site of HIV-1 reverse transcriptase. Ulonivirine can be used in studies related to HIV-1 infection .

HY-W011235

Norfluoxetine hydrochloride	5-HT Receptor Calcium Channel Drug Metabolite	Cardiovascular Disease Neurological Disease
Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity .

HY-18063

ML252	Potassium Channel Cytochrome P450	Neurological Disease
ML252 is a selective inhibitor of KCNQ2 (Kv7.2) channel with an IC₅₀s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 also inhibits **Cytochrome P450 with IC₅₀**s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 shows highly brain penetrant .

HY-N5132

(-)-Fenchone	Cytochrome P450	Others
(-)-Fenchone is a bicyclic monoterpene and serves as a substrate for human liver microsomal cytochrome P450 enzymes CYP2A6 and CYP2B6. (-)-Fenchone is not metabolized by human CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 enzymes. (-)-Fenchone undergoes hydroxylation to produce 6-exo-hydroxyfenchone, 6-endo-hydroxyfenchone, and 10-hydroxyfenchone. During the metabolism of (-)-Fenchone, CYP2A6 may play a more important role than CYP2B6 .

HY-W013268

(S)-(+)-N-3-Benzylnirvanol (+)-N-3-Benzylnirvanol	Cytochrome P450	Metabolic Disease
(S)-(+)-N-3-Benzylnirvanol ((+)-N-3-Benzylnirvanol) is a selective and competitive cytochrome P450 (CYP) isoform CYP2C19 inhibitor with a K_i of 250 nM. (S)-(+)-N-3-Benzylnirvanol has low activity against CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 .

HY-116862

Dibenzylfluorescein DBF	Cytochrome P450 Fluorescent Dye	Others
Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 μM (Ex=485 nm，Em=535 nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

HY-150574

CYP3A4-IN-1	Cytochrome P450	Infection
CYP3A4-IN-1 (compound 5a) is a potent **cytochrome P450 3A4 (CYP3A4) inhibitor with an IC₅₀** value of 0.085 µM .

HY-B0383A

Almotriptan PNU180638 free base	5-HT Receptor	Neurological Disease
Almotriptan (PNU180638 free base) is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan can be used in research related to migraine .

HY-124542

5-Hydroxydiclofenac	Drug Metabolite Apoptosis	Cancer
5-Hydroxydiclofenac is a major metabolite of Diclofenac (HY-15036). 5-Hydroxydiclofenac is formed by the cytochrome P450 (CYP) isoforms CYP3A4, CYP2C189, CYP2C19, and CYP2C8. 5-Hydroxydiclofenac shows apoptotic effects in hepatocytes .

HY-17356S

Fenofibrate-d6	Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-150084

(±)14,15-Epoxyeicosatrienoic acid (±)14(15)-EET	Cytochrome P450 Mitosis	Cancer
(±)14,15-Epoxyeicosatrienoic acid ((±)14(15)-EET) is the Cytochrome P450 metabolite of arachidonic acid. While CYP3A4 may be involved in breast cancer cell growth, (±)14,15-Epoxyeicosatrienoic acid may promote mitosis and anchorage-dependent cloning through STAT3 affected by CYP3A4. (±)14,15-Epoxyeicosatrienoic acid exhibits STAT3-dependent cell growth promotion and may also participate in the autocrine/paracrine pathway that drives cell growth .

HY-126983

6',7'-Epoxybergamottin Epoxybergamottin	Cytochrome P450	Others
6',7'-Epoxybergamottin is a metabolism of Penicillium digitatum. 6',7'-Epoxybergamottin can be used in study the cytochrome **P450 3A4** inhibitory activity .

HY-133152

Brexpiprazole S-oxide DM-3411	5-HT Receptor Dopamine Receptor	Neurological Disease
Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT_1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT_2A receptor antagonist with a K_i of 0.47 nM .

HY-113031

16a-Hydroxydehydroisoandrosterone 16α-Hydroxy-DHEA; 16α-OH-DHEA; 16α-hydroxy DHEA	Cytochrome P450	Endocrinology
16a-Hydroxydehydroisoandrosterone (16α-Hydroxy-DHEA) is a metabolite of the endogenous steroid hormone dehydroepiandrosterone. 16α-hydroxy Dehydroepiandrosterone is formed from dehydroepiandrosterone via 16-hydroxylation by the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in adult human liver microsomes, as well as by fetal recombinant CYP3A7. It is a precursor to fetal estrogens, including estriol.

HY-N0926A

Columbamine chloride 1 Publications Verification Columbamin chloride; Dehydroisocorypalmine chloride	Cytochrome P450 Apoptosis Parasite	Infection Neurological Disease Inflammation/Immunology Cancer
Columbamine (Columbamin; Dehydroisocorypalmine) chloride is an organic heterotetracyclic alkaloid extracted from plants. Columbamine chloride is a metabolite of Berberine (HY-N0716). Columbamine chloride inhibits the cytochrome P450 (CYP) isoform CYP3A4 (IC50 = 30.6 µM). Columbamine chloride induces apoptosis in cancer cells. Columbamine chloride can be used for antioxidant, anti-inflammatory, antitumor, antifungal, antiparasite, hepatoprotective, neuroprotective, hypolipidemic and hypoglycemic study .

HY-17356R

Fenofibrate (Standard) Maximum Cited Publications 33 Publications Verification	Reference Standards PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

HY-135161

EDDP perchlorate	Drug Metabolite	Others
EDDP perchlorate is an N-desmethyl metabolite of Methadone by intestinal, hepatic, and cytochrome P450 (CYP) 3A4 .

HY-W587878

Thujopsene	Cytochrome P450 Pyruvate Kinase Fungal Apoptosis Insecticide	Infection Cancer
Thujopsene is the inhibitor for **cytochrome P450, that inhibits CYP2B6, CYP3A4, CYP2C19, CYP2C8, CYP2C9 with IC₅₀s of 1.3, 12.6, 13.6, 29.8, and 44.9 μM, respectively. Thujopsene binds to PKM2, inhibits the metabolism pathway of cancer cell, induces apoptosis** in MKN45, thereby exhibiting antitumor efficacy. Thujopsene exhibits anti-termite and antifungal activities through autoxidation .

HY-133152S

Brexpiprazole S-oxide-d8 DM-3411 d₈	Isotope-Labeled Compounds 5-HT Receptor Dopamine Receptor	Neurological Disease
Brexpiprazole S-oxide-d₈ (DM-3411 D₈) is a deuterium labeled Brexpiprazole S-oxide (HY-133152). Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM .

HY-100638

RPR132595A NPC	Drug Metabolite	Cancer
RPR132595A (NPC) is an active metabolite of CPT-11, which is generated by **cytochrome P-450 3A4 (CYP3A4)** and finally excreted through urine .

HY-150580

CYP3A4-IN-2	Cytochrome P450	Inflammation/Immunology Cancer
CYP3A4-IN-2 is a specific inhibitor of **cytochrome P450 3A4 (CYP3A4) with the IC₅₀** value of 0.055 μM. CYP3A4-IN-2 is a ritonavir analogue with increased hydrophobicity of the R2 side group and stronger inhibitory effect compared to ritonavir. CYP3A4-IN-2 can be used as an antiviral agent and immunosuppressants .

HY-W075315

Xanthine oxidoreductase-IN-6	MOFs Xanthine Oxidase Cytochrome P450	Metabolic Disease
Xanthine oxidoreductase-IN-6 (Compound 4) is an orally active xanthine oxidoreductase (XOR) inhibitor with an IC₅₀ of 170 nM. Xanthine oxidoreductase-IN-6 can block the final step of uric acid biosynthesis and lower serum uric acid levels. Xanthine oxidoreductase-IN-6 also shows **Cytochrome P450 3A4** (CYP3A4) inhibitory activity. Xanthine oxidoreductase-IN-6 can be used for the research of hyperuricemia .

HY-N10421

Dihydrocubebin (-)-Dihydrocubebin	Cytochrome P450	Others
Dihydrocubebin is a compound isolated from Piper cubeba as potent and selective inhibitors against cytochrome P450 3A4 (CYP3A4) .

HY-100638A

RPR132595A hydrochloride NPC hydrochloride	Drug Metabolite	Cancer
RPR132595A (NPC) hydrochloride is an active metabolite of CPT-11, which is generated by **cytochrome P-450 3A4 (CYP3A4)** and finally excreted through urine .

HY-131527R

Wy-45494 hydrochloride (Standard) N-Desmethyl Venlafaxine hydrochloride (Standard); Wy 45494 (Standard)	Serotonin Transporter Reference Standards	Metabolic Disease
Wy-45494 (hydrochloride) (Standard) is the analytical standard of Wy-45494 (hydrochloride). This product is intended for research and analytical applications. Wy-45494 hydrochloride (N-Desmethyl Venlafaxine hydrochloride; Wy 45494) is a minor active metabolite of the selective norepinephrine and serotonin reuptake inhibitor (SNRI) venlafaxine. It is formed from venlafaxine via the cytochrome P450 (CYP) isomer CYP3A4.2. Wy-45494 hydrochloride inhibits norepinephrine and serotonin reuptake in rat synaptosomal preparations (IC50s of 4.7 and 1.6 μM, respectively). In vivo, Wy-45494 hydrochloride reversed reserpine-induced hypothermia in mice at a minimum effective dose (MED) of 10 mg/kg.

HY-132545S

RPR132595A-d3 NPC-d₃	Isotope-Labeled Compounds Topoisomerase	Cancer
RPR132595A-d₃ is the deuterium labeled RPR132595A. RPR132595A is an active metabolite of Irinotecan (CPT-11), which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine .

HY-177997

α-Hydroxysalmeterol	Drug Metabolite	Neurological Disease
α-Hydroxysalmeterol is a metabolite that can be formed via cytochrome P450 isoform 3A4-induced hydroxylation of Salmeterol (HY-14302). α-Hydroxysalmeterol is a potentially relevant urine biomarker to include when screening for Salmeterol misuse .

HY-17570R

Desoximetasone (Standard) 1 Publications Verification	Glucocorticoid Receptor Reference Standards Interleukin Related Cytochrome P450	Inflammation/Immunology
Desoximetasone (Standard) is the analytical standard of Desoximetasone (HY-17570). This product is intended for research and analytical applications. Desoximetasone is a corticosteroid and a substrate of **cytochrome P450 3A4**. Desoximetasone has anti-inflammatory, anti-allergic, and immunosuppressive effects. Desoximetasone can be used in the research of various skin diseases, such as skin allergies, atopic dermatitis, and psoriasis .

HY-150581

CYP3A4-IN-3	Cytochrome P450	Infection Inflammation/Immunology
CYP3A4-IN-3 is a high-affinity specific inhibitor of **cytochrome P450 3A4 (CYP3A4) with the IC₅₀** value of 0.075 μM. CYP3A4-IN-3 is a ritonavir analogue, but with a simpler structure and twice the inhibitory effect of ritonavir. CYP3A4-IN-3 is used as an antiviral agent and immunosuppressant .

HY-W739812

Carboxy finasteride Finasteride carboxylic acid	Aldose Reductase	Cancer
Carboxy finasteride is a metabolite of the 5α-reductase inhibitor Finasteride (HY-13635). Finasteride is biotransformed by cytochrome P450 (CYP3A4) and is successively oxidized to Hydroxy finasteride and Carboxy finasteride. Carboxy finasteride is the major metabolite in urine, while Hydroxy finasteride is the major metabolite in plasma .

HY-137310

4-Hydroxy atorvastatin hemicalcium	HMG-CoA Reductase (HMGCR) Drug Metabolite	Metabolic Disease
4-Hydroxy atorvastatin hemicalcium is a metabolite of Atorvastatin (HY-B0589). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 to form 4-hydroxy atorvastatin .

HY-Z2667

(R)-Esomeprazole (R)-Omeprazole; (+)-Omeprazole	Cytochrome P450	Metabolic Disease Inflammation/Immunology
(R)-Esomeprazole ((R)-Omeprazole; (+)-Omeprazole) is an orally active **cytochrome P450** 2C19, CYP3A4, and CYP2C9-related metabolic modulator. (R)-Esomeprazole can be used in studies of digestive system diseases and compound metabolic interactions .

HY-127059

Clindamycin Sulfoxide U-25026A	Antibiotic	Metabolic Disease
Clindamycin sulfoxide is an active metabolite of the antibiotic Clindamycin (HY-B1455). It is formed via S-oxidation of clindamycin primarily by the cytochrome P450 (CYP) isoform CYP3A4. Clindamycin sulfoxide inhibits the growth of P. prevotti, B. fragilis, and C. sordelli in vitro with MIC values of 2, 2, and 1 mg/L, respectively.

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

HY-N6972R

Cepharanthine (Standard)	Autophagy Reference Standards SARS-CoV Cytochrome P450 Apoptosis Parasite	Infection Inflammation/Immunology Cancer
Cepharanthine (Standard) is the analytical standard of Cepharanthine. This product is intended for research and analytical applications. Cepharanthine is a natural product that can be isolated from the plant Stephania?cephalantha?Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46?μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

HY-137580

N-Desmethyl Eletriptan	Cytochrome P450	Metabolic Disease
N-desmethyl Eletriptan is a metabolite of Eletriptan (HY-A0039). It is formed from eletriptan primarily by the cytochrome P450 (CYP) isoform CYP3A4 in human liver microsomes.

HY-N8094

Kushenol M	Cytochrome P450	Others
Kushenol M is a flavonoid from Sophora flavescens. Kushenol M is a cytochrome P450 (CYP) inhibitor, with IC₅₀ values of 1.29 μM for CYP3A4 in human liver microsomes .

HY-W749323

21-Hydroxyeplerenone	Mineralocorticoid Receptor	Cardiovascular Disease
21-Hydroxyeplerenone is a major metabolite of the mineralocorticoid receptor antagonist Eplerenone (HY-B0251). 21-Hydroxyeplerenone is formed from eplerenone by the cytochrome P450 (CYP) isoform CYP3A4.

HY-Z2493

Aripiprazole N1-oxide	Dopamine Receptor	Neurological Disease
Aripiprazole N-oxide is a metabolite of the atypical antipsychotic Aripiprazole (HY-14546). Aripiprazole N-oxide is formed from aripiprazole by the cytochrome P450 (CYP) isoforms CYP2D6 and CYP3A4.

HY-182602

KOSN 1724	Microtubule/Tubulin Cytochrome P450	Cancer
KOSN 1724 is an anticancer agent. KOSN 1724 disrupts tubulin activity, stabilizes microtubules, and inhibits cancer cells proliferation. KOSN 1724 inhibits **cytochrome P450** 3A4, CYP2C9, and CYP2C19 activity. KOSN 1724 can be used for the research of cancer .

HY-149977

Anticancer agent 111	Cytochrome P450	Cancer
Anticancer agent 111 (compound 11) is a potent **cytochrome P450 inhibitor with an IC₅₀** value of 3 μM for CYP3A4. Anticancer agent 111 has anticancer activity. Anticancer agent 111 can be used in research of cancer .

HY-W740175

6b-Hydroxy triamcinolone acetonide	Glucocorticoid Receptor	Inflammation/Immunology
6b-Hydroxy triamcinolone acetonide is a metabolite of the synthetic corticosteroid Triamcinolone acetonide (HY-B0636). 6b-Hydroxy triamcinolone acetonide is formed from triamcinolone acetonide by the cytochrome P450 (CYP) isoforms CYP3A4, CYP3A5, and CYP3A7.

HY-14294

Capravirine S-1153	Reverse Transcriptase HIV	Infection
Capravirine (S-1153) is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent antiviral activity. Capravirine inhibits replication of HIV-1 strains that are resistant to nucleoside/nucleotide reverse transcriptase inhibitors and other NNRTIs. Capravirine is metabolized by the cytochrome P450 enzyme CYP3A4 .

HY-135390

Hydroxy desmethyl Bosentan Ro 64-1056	Drug Metabolite	Cardiovascular Disease
Hydroxy desmethyl Bosentan (Ro 64-105) is a Bosentan metabolism produced by the cytochrome P450 enzymes CYP2C9 and CYP3A4 in the liver . Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively. Bosentan can be used in treatment of pulmonary arterial hypertension .

Cat. No.	상품명

HY-L922

Good ADMET Diversity Library

25000 compounds

A diverse compound library with favorable ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity) is crucial in drug discovery. Early evaluation of ADMET properties allows for the exclusion of molecules with unfavorable profiles at the initial stages, thereby reducing the risk of late-stage development failures, lowering R&D costs, and accelerating optimization of lead compounds. Based on predictions from ADMET-related AI algorithms, the compounds in this library are predicted to exhibit favorable oral bioavailability (F > 30%), reasonable plasma protein binding (PPB < 98%), minimized CYP3A4 inhibition potential (inhibition probability < 50%, CYP3A4 is the most critical drug-metabolizing enzyme in the cytochrome P450 family) , low toxicity profiles, with 140 potentially toxic substructures pre-identified and excluded via substructure searching to eliminate compounds containing hazardous fragments. The diversity library enables broad applicability in high-throughput screening (HTS) and high-content screening (HCS).

Cat. No.	상품명	Type

HY-116862

Dibenzylfluorescein

DBF

Fluorescent Dyes

Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 μM (Ex=485 nm，Em=535 nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

HY-17356G

Fenofibrate

Fluorescent Dyes

Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Cat. No.	상품명	Type

HY-17356G

Fenofibrate

Biochemical Assay Reagents

Cat. No.	Compare	상품명	Species	Source	Image

HY-P74210

	CYP3A4 Protein, Human (His) 1 Publications Verification cytochrome P450 3A4; CYPIIIA3; CYP3A4; CYP3A3	Human	E. coli
	The CYP3A4 protein, encoded by the CYP3A4 gene, is a key enzyme in drug metabolism and the synthesis of cholesterol, steroids, and lipids. It localizes to the endoplasmic reticulum and is induced by glucocorticoids and certain drugs. CYP3A4 Protein, Human (His) is the recombinant human-derived CYP3A4 protein, expressed by E. coli , with N-10*His labeled tag.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명	Chemical Structure

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-133152S

Brexpiprazole S-oxide-d8

Brexpiprazole S-oxide-d₈ (DM-3411 D₈) is a deuterium labeled Brexpiprazole S-oxide (HY-133152). Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM .

HY-132545S

RPR132595A-d3
RPR132595A-d₃ is the deuterium labeled RPR132595A. RPR132595A is an active metabolite of Irinotecan (CPT-11), which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine .

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .

HY-127059S

Clindamycin sulfoxide-13C,d3

Clindamycin sulfoxide- ¹³C,d₃ (U-25026A- ¹³C,d₃) is the deuterium and ¹³C-labeled Clindamycin sulfoxide (HY-127059). Clindamycin sulfoxide is an active metabolite of the antibiotic Clindamycin (HY-B1455). It is formed via S-oxidation of clindamycin primarily by the cytochrome P450 (CYP) isoform CYP3A4. Clindamycin sulfoxide inhibits the growth of P. prevotti, B. fragilis, and C. sordelli in vitro with MIC values of 2, 2, and 1 mg/L, respectively.

Host:	Mouse (2) Rabbit (1)
Reactivity:	Human (3) Rat (2) Mouse (2)
Application:	IHC-P (3) ICC/IF (2) IP (1) WB (3) FC (2) ELISA (2)
Isotype:	IgG (1) IgG1 (2)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P84018

	Cytochrome P450 3A4 Antibody (YA3715) HLP; CP33; CP34; CYP3A; NF-25; CYP3A3; P450C3; CYPIIIA3; CYPIIIA4; P450PCN1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Rat
	Cytochrome P450 3A4 Antibody (YA3715) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytochrome P450 3A4.

HY-P83620

	Cytochrome P450 3A4 Antibody (YA3365) HLP; CP33; CP34; CYP3A; NF-25; CYP3A3; P450C3; CYPIIIA3; CYPIIIA4; P450PCN1; CYP3A4	WB, IHC-P, IP	Human
	Cytochrome P450 3A4 Antibody (YA3365) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytochrome P450 3A4.

HY-P84018A

	Cytochrome P450 3A4 Antibody (YA3715)(PBS only) HLP; CP33; CP34; CYP3A; NF-25; CYP3A3; P450C3; CYPIIIA3; CYPIIIA4; P450PCN1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Rat
	Cytochrome P450 3A4 Antibody (YA3715) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytochrome P450 3A4.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명		Classification

HY-115824

7ETMC		Alkynes
7ETMC is a cytochrome P450 inhibitor with selective inhibition of human cytochrome P450s 1A1 and 1A2. 7ETMC has inhibitory effects on P450s 1A1 and 1A2 with IC?? values of 0.46μM and 0.50μM, respectively, within the first six minutes, and has no inhibitory activity against P450s 2A6 and 2B1. Except for 7-ethynyl-3-methyl-4-phenylcoumarin, the remaining inhibitors show mechanism-based inhibition of P450s 1A1 and 1A2.

Targets Recommended: Cytochrome P450

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and *CYP3A4*, respectively.

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

cytochrome P450 3A4

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

GMP Molecules

Natural
Products